Context Therapeutics Inc. (CNTX) - Dilution Analysis

10-Q filing | 95.2M shares outstanding

10-K filing | 95.2M shares outstanding

10-Q filing | 95.2M shares outstanding

8-K filing: Context Therapeutics Inc. amended its sales agreement with Leerink Partners LLC to increase the aggregate offering amount to $75.0 million and suspended the use of the prior ATM sales prospectus after selling 14,705,882 shares for $15.0 million. ($15.0M proceeds)

10-Q filing | 95.2M shares outstanding

10-Q filing | 95.2M shares outstanding

10-K filing | 89.7M shares outstanding

8-K filing: Context Therapeutics Inc. sold 14,705,882 shares of its common stock for aggregate gross proceeds of approximately $15 million. ($15.0M proceeds)

10-Q filing | 80.5M shares outstanding

S-3 filing: The company may issue rights to purchase common stock or preferred stock, or units consisting of any combination of the other types of securities offered under this prospectus.

10-Q filing | 75.0M shares outstanding

S-3 filing: Context Therapeutics Inc. is offering up to 64,515,000 shares of common stock by the Selling Stockholders, including shares issuable upon exercise of Pre-Funded Warrants.

10-Q filing | 75.0M shares outstanding

10-K filing | 16.0M shares outstanding

10-Q filing | 16.0M shares outstanding

10-Q filing | 16.0M shares outstanding

10-Q filing | 16.0M shares outstanding

10-K filing | 16.0M shares outstanding

POS AM filing: This POS AM filing relates to an offering of up to 5,000,000 shares of common stock by selling stockholders. The company will not receive any proceeds from the sale of these shares.

S-3 filing: The filing describes a shelf registration for the potential issuance of rights to purchase common stock or preferred stock, as well as units consisting of various combinations of securities.

10-Q filing | 16.0M shares outstanding

10-Q filing | 16.0M shares outstanding

10-Q filing | 16.0M shares outstanding

POS AM filing: This POS AM filing registers up to 10,000,000 shares of common stock for sale by selling stockholders, who may sell the shares from time to time at varying prices. The company will not receive any proceeds from the sale of these shares.

10-K filing | 16.0M shares outstanding

S-1 filing: This S-1 filing relates to the disposition of up to 10,000,000 shares of Context Therapeutics Inc.'s common stock by selling stockholders.

10-Q filing | 11.0M shares outstanding

S-1/A filing: This is an S-1/A filing related to ThinkEquity acting as underwriter. The underwriter received warrants to purchase 4,882 shares of common stock exercisable at a price of $7.17 per share in connection with acting as a placement agent on the Company’s private placements.

S-1/A filing: This is an S-1/A filing by ThinkEquity, related to the closing of private placements on February 18, 2021 and March 5, 2021. ThinkEquity received warrants to purchase 4,882 shares of common stock exercisable at a price of $7.17 per share and will receive 2,381 shares of common stock pursuant to conversion.

S-1/A filing: This S-1/A filing with ThinkEquity as underwriter, discusses the potential for stabilizing transactions, syndicate covering transactions, and penalty bids. It also mentions the underwriter received warrants to purchase 4,882 shares of common stock exercisable at a price of $7.17 per share and will receive 2,381 shares of common stock.

S-1/A filing: The filing is an S-1/A by ThinkEquity, detailing potential market-making activities and relationships, including warrants received for acting as a placement agent in previous private placements.

S-1/A filing: This is an S-1/A filing detailing recent sales of unregistered securities, including convertible notes, Series Seed Convertible Preferred Units, and Series A Convertible Preferred Units.

S-1 filing: The filing is an S-1 registration statement with ThinkEquity as the underwriter, discussing various aspects of a potential offering, including underwriter responsibilities, stabilization activities, and potential future engagements.